1. Pink Sheet
  2. >>Legal & IP

Patent Office Opposes Ruling On Ovarian Cancer Drug, Wants Stronger Obviousness Standard

 
• By Brenda Sandburg

After Federal Circuit vacates district court ruling that patent on method of dosing ImmunoGen’s mirvetuximab soravtansine is indefinite and obvious, PTO warns of ‘well-documented problem’ of drug manufacturers receiving follow-on patents for ‘trivial modifications’ that delay generics.

Ovarian cancer
USPTO is opposed to issuing patent on method of dosing ImmunoGen's ovarian cancer drug • Source: Shutterstock

The US Patent and Trademark Office took the unusual step of voicing concerns about the misuse of patent laws in a petition seeking a panel rehearing of a decision by the US Court of Appeals for the Federal Circuit. The commentary reflects the desire of the Biden Administration and members of Congress for the agency to consider the impact of patent practices on access to affordable drugs.

The Federal Circuit vacated a district court ruling that ImmunoGen, Inc.’s patent claims on a method of dosing its investigational antibody-drug conjugate mirvetuximab soravtansine are “fatally indefinite and fatally...

More from Legal & IP

More from Pink Sheet

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By Vibha Sharma

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.